| 1 Eradication of MRSA (negative MRSA respiratory culture following treatment) |
1 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 1.1 At day 28 |
1 |
41 |
Odds Ratio (M‐H, Fixed, 95% CI) |
12.60 [2.84, 55.84] |
| 1.2 At day 168 |
1 |
36 |
Odds Ratio (M‐H, Fixed, 95% CI) |
1.17 [0.31, 4.42] |
| 2 Eradication of MRSA (3 negative MRSA respiratory cultures over 6 months) |
1 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 2.1 At 6 months |
1 |
61 |
Odds Ratio (M‐H, Fixed, 95% CI) |
1.80 [0.62, 5.25] |
| 3 FEV1 (L) ‐ absolute change from baseline |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 3.1 At day 28 |
1 |
35 |
Mean Difference (IV, Fixed, 95% CI) |
0.11 [‐0.01, 0.23] |
| 3.2 At day 168 |
1 |
31 |
Mean Difference (IV, Fixed, 95% CI) |
0.06 [‐0.06, 0.18] |
| 4 FEV1 (L) ‐ relative change from baseline |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 4.1 At day 28 |
1 |
35 |
Mean Difference (IV, Fixed, 95% CI) |
4.89 [‐0.61, 10.39] |
| 4.2 At day 168 |
1 |
31 |
Mean Difference (IV, Fixed, 95% CI) |
3.08 [‐2.21, 8.37] |
| 5 FEV1 (% predicted) ‐ absolute change from baseline |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 5.1 At day 28 |
1 |
35 |
Mean Difference (IV, Fixed, 95% CI) |
4.79 [‐0.89, 10.47] |
| 5.2 At day 168 |
1 |
31 |
Mean Difference (IV, Fixed, 95% CI) |
4.68 [‐0.29, 9.65] |
| 6 Overall anti‐MRSA antibiotic use |
1 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 6.1 At day 28 |
1 |
45 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.80 [0.24, 2.64] |
| 7 Patient outcomes (absolute change from baseline) measured using CFRSD‐CRISS |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 7.1 At day 28 |
1 |
41 |
Mean Difference (IV, Fixed, 95% CI) |
‐6.72 [‐14.36, 0.92] |
| 7.2 At day 168 |
1 |
37 |
Mean Difference (IV, Fixed, 95% CI) |
5.14 [‐5.06, 15.34] |
| 8 Patient outcome (absolute change from baseline) measured using CFQ‐R RSS |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 8.1 At day 28 |
1 |
40 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.26 [‐11.32, 10.80] |
| 8.2 At day 168 |
1 |
37 |
Mean Difference (IV, Fixed, 95% CI) |
‐3.94 [‐13.96, 6.08] |
| 9 Participants positive for Pseudomonas aeruginosa |
1 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 9.1 At screening |
1 |
45 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.85 [0.18, 3.92] |
| 9.2 At day 28 |
1 |
41 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.59 [0.11, 3.06] |
| 9.3 At day 84 |
1 |
37 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.57 [0.11, 3.02] |
| 9.4 At day 168 |
1 |
36 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.67 [0.11, 3.87] |
| 10 Weight (kg) (absolute change from baseline) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 10.1 At day 28 |
1 |
43 |
Mean Difference (IV, Fixed, 95% CI) |
0.07 [‐0.77, 0.91] |
| 10.2 At day 168 |
1 |
38 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.19 [‐1.70, 1.32] |
| 11 Adverse effects to treatment |
1 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 11.1 Gastrointestinal disorders |
1 |
45 |
Odds Ratio (M‐H, Fixed, 95% CI) |
2.71 [0.75, 9.79] |
| 11.2 Skin and subcutaneous tissue disorders |
1 |
45 |
Odds Ratio (M‐H, Fixed, 95% CI) |
5.26 [0.56, 49.29] |
| 11.3 Injury, poisoning and procedural complications |
1 |
45 |
Odds Ratio (M‐H, Fixed, 95% CI) |
7.0 [0.34, 143.85] |
| 11.4 Nervous system disorders |
1 |
45 |
Odds Ratio (M‐H, Fixed, 95% CI) |
4.78 [0.22, 105.36] |
| 11.5 General disorders and administration site conditions |
1 |
45 |
Odds Ratio (M‐H, Fixed, 95% CI) |
2.86 [0.27, 29.80] |
| 11.6 Renal and urinary disorders |
1 |
45 |
Odds Ratio (M‐H, Fixed, 95% CI) |
2.74 [0.11, 71.04] |
| 11.7 Musculoskeletal and connective tissue disorders |
1 |
45 |
Odds Ratio (M‐H, Fixed, 95% CI) |
2.74 [0.11, 71.04] |
| 11.8 Immune system disorders |
1 |
45 |
Odds Ratio (M‐H, Fixed, 95% CI) |
2.74 [0.11, 71.04] |
| 11.9 Eye disorders |
1 |
45 |
Odds Ratio (M‐H, Fixed, 95% CI) |
1.82 [0.15, 21.62] |
| 11.10 Ear and labyrinth disorders |
1 |
45 |
Odds Ratio (M‐H, Fixed, 95% CI) |
1.82 [0.15, 21.62] |
| 11.11 Infections and infestations |
1 |
45 |
Odds Ratio (M‐H, Fixed, 95% CI) |
1.36 [0.20, 9.02] |
| 11.12 Psychiatric disorders |
1 |
45 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.87 [0.05, 14.82] |
| 11.13 Blood and lymphatic system disorders |
1 |
45 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.87 [0.05, 14.82] |
| 11.14 Metabolism and nutrition disorders |
1 |
45 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.86 [0.11, 6.73] |
| 11.15 Investigations |
1 |
45 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.86 [0.15, 4.79] |
| 11.16 Congenital, familial and genetic disorders |
1 |
45 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.28 [0.01, 7.22] |
| 12 Number of participants with pulmonary exacerbations |
1 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 12.1 At day 28 |
1 |
45 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.29 [0.06, 1.30] |
